16 citations
,
April 2007 in “Journal of Obstetrics and Gynaecology Research” Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
June 2023 in “SPIRE - Sciences Po Institutional REpository” Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.
12 citations
,
October 2018 in “Aging male/The aging male” Higher BMI and lower testosterone are linked to more aggressive prostate cancer.
45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
113 citations
,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
15 citations
,
October 2014 in “Hormone Molecular Biology and Clinical Investigation” Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
10 citations
,
October 2012 in “Andrology” Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.
Early-onset baldness is linked to genetics, lifestyle, and can indicate higher risk for heart and metabolic diseases, and affects mental health.
25 citations
,
June 2019 in “Endocrine Related Cancer” Mutations in certain receptors can cause diseases and offer new treatment options.
451 citations
,
March 2005 in “Endocrine Reviews” The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.
28 citations
,
July 2017 in “Journal of Endocrinological Investigation” Early onset baldness in men may indicate a condition similar to PCOS, linked to heart disease, diabetes, and prostate issues.
6 citations
,
May 2016 in “Urolithiasis” Balding and low testosterone increase risk of urinary stones.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
April 2003 in “Experimental Dermatology” The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” Steroid-producing capabilities in certain cancers may contribute to treatment resistance.
27 citations
,
February 2014 in “BMC Cancer” Circadian rhythm disruption, chronic inflammation, hormones, metabolism, and genetics may increase prostate cancer risk.
50 citations
,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
1 citations
,
January 2009 in “Trepo - Institutional Repository of Tampere University” Vitamin D may help regulate cholesterol and influence prostate cancer development.
August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
11 citations
,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
101 citations
,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
3 citations
,
September 2016 in “Natural Product Communications” Germacrene analogs, especially 8-Hydroxy germacrene B, are more effective than germacrone at blocking a hormone-related enzyme and could help treat hair loss.
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
8 citations
,
July 2021 in “F1000Research” Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.
18 citations
,
October 2021 in “Frontiers in Physiology” Lipocalin-Type Prostaglandin D2 Synthase (L-PGDS) is a protein that plays many roles in the body, including sleep regulation, pain management, food intake, and protection against harmful substances. It also affects fat metabolism, glucose intolerance, cell maturation, and is involved in various diseases like diabetes, cancer, and arthritis. It can influence sex organ development and embryonic cell differentiation, and its levels can be used as a diagnostic marker for certain conditions.